Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cisatracurium Besylate

FDA-approved product (injectable, injection), marketed as Cisatracurium Besylate, Cisatracurium Besylate Preservative Free, Nimbex and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cisatracurium Besylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Cisatracurium Besylate. Its therapeutic class is shown instead.

WHO therapeutic group
Other quaternary ammonium compounds
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cisatracurium Besylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cisatracurium Besylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Cisatracurium and Sufentanil Consumption Using a Closed Loop Computer Control Infusion System

    NCT01785446 · start 2012-11

    Registered record
    Registry ID
    NCT01785446
    Conditions
    The Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index.; Effect of Dexmedetomidine on Sufentanil Consumption.; Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age Groups.
    Interventions
    Effect of dexmedetomidine on cisatracurium and sufentanil consumption; Consumption of cisatracurium and sufentanil in different age groups.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2012-11
    Completion
    Not recorded
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index.; Effect of Dexmedetomidine on Sufentanil Consumption.; Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age Groups.
    InterventionEffect of dexmedetomidine on cisatracurium and sufentanil consumption; Consumption of cisatracurium and sufentanil in different age groups.
    PhaseNot applicable
    Registry statusUnknown

  • Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia

    NCT01651572 · start 2012-07

    Registered record
    Registry ID
    NCT01651572
    Conditions
    Postoperative Residual Curarization; Residual Neuromuscular Block
    Interventions
    Cisatracurium; Rocuronium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-07
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Residual Curarization; Residual Neuromuscular Block
    InterventionCisatracurium; Rocuronium
    PhasePhase 4
    Registry statusCompleted

  • Minimal Alveolar Concentration of Sevoflurane Inducing Isoelectric Electroencephalogram

    NCT01662622 · start 2012-03

    Registered record
    Registry ID
    NCT01662622
    Conditions
    Middle Aged Patients; Sevoflurane; General Anesthesia
    Interventions
    Sevoflurane
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-03
    Completion
    2012-07
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMiddle Aged Patients; Sevoflurane; General Anesthesia
    InterventionSevoflurane
    PhasePhase 4
    Registry statusCompleted

  • Quantitative Electroencephalogram and Bispectral Index Brain Mapping During Propofol vs Sevoflurane General Anesthesia

    NCT05102422 · start 2007-08-21

    Registered record
    Registry ID
    NCT05102422
    Conditions
    Neurophysiology
    Interventions
    Propofol 1 % Injectable Suspension; Sevoflurane inhalant product
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-08-21
    Completion
    2009-12-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurophysiology
    InterventionPropofol 1 % Injectable Suspension; Sevoflurane inhalant product
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Nitrous Oxide on Cisatracurium Infusion Demands

    NCT01152905 · start 2007-04

    Registered record
    Registry ID
    NCT01152905
    Conditions
    Neuromuscular Blocking Agents
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-04
    Completion
    2008-07
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromuscular Blocking Agents
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted